RU2016111137A - Сконструированные конъюгаты против dll3 и способы применения - Google Patents
Сконструированные конъюгаты против dll3 и способы применения Download PDFInfo
- Publication number
- RU2016111137A RU2016111137A RU2016111137A RU2016111137A RU2016111137A RU 2016111137 A RU2016111137 A RU 2016111137A RU 2016111137 A RU2016111137 A RU 2016111137A RU 2016111137 A RU2016111137 A RU 2016111137A RU 2016111137 A RU2016111137 A RU 2016111137A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- conjugate
- dll3
- paragraphs
- drug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Claims (28)
1. Конъюгат антитела с лекарственным средством с формулой:
Ab-[L-D]n или его фармацевтически приемлемая соль, где
a) Ab включает антитело к DLL3 с одним или более неспаренными цистеинами;
b) L содержит необязательный линкер;
c) D содержит ПБД; и
d) n представляет собой целое число приблизительно от 1 до приблизительно 8.
2. Конъюгат антитела с лекарственным средством по п. 1, где антитело к DLL3 содержит моноклональное антитело.
3. Конъюгат антитела с лекарственным средством по пп. 1 или 2, где антитело к DLL3 содержит интернализированное антитело.
4. Конъюгат антитела с лекарственным средством по любому из пп. 1-3, где антитело к DLL3 содержит гуманизированное антитело или антитело с привитой CDR.
5. Конъюгат антитела с лекарственным средством по любому из пп. 1-4, где антитело к DLL3 содержит два неспаренных цистеина.
6. Конъюгат антитела с лекарственным средством по любому из пп. 1-5, где антитело к DLL3 содержит легкую цепь каппа.
7. Конъюгат антитела с лекарственным средством по п. 6, где антитело к DLL3 содержит легкую цепь, где C214 включает неспаренный цистеин.
8. Конъюгат антитела с лекарственным средством по любому из пп. 1-7, где антитело к DLL3 содержит тяжелую цепь IgG1.
9. Конъюгат антитела с лекарственным средством по п. 8, где антитело к DLL3 содержит тяжелую цепь, где C220 включает неспаренный цистеин.
10. Конъюгат антитела с лекарственным средством по любому из пп. 1-9, где антитело к DLL3 выбрано из группы, состоящей из hSC16.13, hSC16.15, hSC16.25, hSC16.34 и hSC16.56, или антитела, которое конкурирует за связывание с DLL3 человека с любым одним из hSC16.13, hSC16.15, hSC16.25, hSC16.34 и hSC16.56.
11. Конъюгат антитела с лекарственным средством по любому из пп. 1-10, где ПБД содержит ПБД, выбранный из группы, состоящей из ПБД1, ПБД2, ПБД3, ПБД4 и ПБД5.
12. Конъюгат антитела с лекарственным средством по любому из пп. 1-11, где конъюгат антитела с лекарственным средством содержит расщепляемый линкер.
13. Конъюгат антитела с лекарственным средством по п. 12, где расщепляемый линкер содержит дипептид.
14. Фармацевтическая композиция, включающая конъюгат антитела с лекарственным средством по любому из пп. 1-13 и фармацевтически приемлемый носитель.
15. Способ лечения рака у субъекта, включающий введение указанному субъекту фармацевтической композиции по п. 14.
16. Способ по п. 15, где рак включает мелкоклеточный рак легких.
17. Способ получения конъюгата антитела с лекарственным средством по любому из пп. 1-13, включающий стадии:
a) создания антитела к DLL3, содержащего неспаренный цистеин;
b) селективного восстановления антитела к DLL3; и
c) конъюгации селективно восстановленного антитела к DLL3 с ПБД.
18. Способ по п. 17, где стадия селективного восстановления антитела к DLL3 включает стадию контакта антитела со стабилизатором.
19. Способ по любому из пп. 17 - 19, дополнительно включающий стадию очистки конъюгата антитела с лекарственным средством с использованием препаративной хроматографии.
20. Конъюгат антитела с лекарственным средством, содержащий АЛС, выбранный из группы, состоящей из АЛС1, АЛС2, АЛС3, АЛС4 и АЛС5, где Ab содержит сконструированное антитело к DLL3.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361871173P | 2013-08-28 | 2013-08-28 | |
US61/871,173 | 2013-08-28 | ||
PCT/US2014/053304 WO2015031693A1 (en) | 2013-08-28 | 2014-08-28 | Engineered anti-dll3 conjugates and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2016111137A true RU2016111137A (ru) | 2017-10-03 |
RU2016111137A3 RU2016111137A3 (ru) | 2018-07-12 |
Family
ID=52587353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016111137A RU2016111137A (ru) | 2013-08-28 | 2014-08-28 | Сконструированные конъюгаты против dll3 и способы применения |
Country Status (16)
Country | Link |
---|---|
US (1) | US20160175460A1 (ru) |
EP (1) | EP3038659A4 (ru) |
JP (1) | JP2016531914A (ru) |
KR (1) | KR20160047567A (ru) |
CN (1) | CN105873612A (ru) |
AU (1) | AU2014312210A1 (ru) |
BR (1) | BR112016004073A8 (ru) |
CA (1) | CA2922544A1 (ru) |
CL (3) | CL2016000468A1 (ru) |
IL (1) | IL244254A0 (ru) |
MX (1) | MX2016002545A (ru) |
PE (1) | PE20160209A1 (ru) |
PH (1) | PH12016500375A1 (ru) |
RU (1) | RU2016111137A (ru) |
SG (1) | SG11201601375VA (ru) |
WO (1) | WO2015031693A1 (ru) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104520324A (zh) | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
MY181648A (en) | 2012-08-24 | 2020-12-30 | Univ California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
TR201908761T4 (tr) | 2013-02-22 | 2019-07-22 | Abbvie Stemcentrx Llc | Antidll3-antikor-pbd konjugatları ve kullanımları. |
WO2015031541A1 (en) | 2013-08-28 | 2015-03-05 | Stem Centrx, Inc. | Novel sez6 modulators and methods of use |
CN105848671B (zh) * | 2013-08-28 | 2019-12-13 | 艾伯维施特姆森特克斯有限责任公司 | 位点特异性抗体缀合方法和组合物 |
EP3107576A4 (en) | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3 antibodies and drug conjugates for use in melanoma |
MA41645A (fr) * | 2015-03-04 | 2018-01-09 | Abbvie Stemcentrx Llc | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation |
GB201506388D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506402D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506394D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506393D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506389D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506407D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506405D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506399D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
CN108025085A (zh) * | 2015-06-23 | 2018-05-11 | 拜耳制药股份公司 | Ksp抑制剂与抗b7h3抗体的抗体药物缀合物(adc) |
AU2016308365A1 (en) * | 2015-08-20 | 2018-03-15 | Abbvie Stemcentrx Llc | Anti-DLL3 antibody drug conjugates and methods of use |
GB201602363D0 (en) * | 2016-02-10 | 2016-03-23 | Adc Therapeutics Sa And Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
RU2756275C2 (ru) | 2016-03-01 | 2021-09-29 | Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. | Антитела, специфические к рецептору полиовируса (pvr) человека |
KR20190022752A (ko) | 2016-06-27 | 2019-03-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
EP3544636B1 (en) | 2017-02-08 | 2021-03-31 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
PL3612537T3 (pl) | 2017-04-18 | 2022-11-07 | Medimmune Limited | Koniugaty pirolobenzodiazepin |
WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
EP3638373A1 (en) | 2017-06-14 | 2020-04-22 | ADC Therapeutics SA | Dosage regimes for the administration of an anti-cd19 adc |
AU2018288030B2 (en) * | 2017-06-20 | 2022-02-03 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (TDC) |
EP3668874B1 (en) | 2017-08-18 | 2021-12-22 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
EP3690038A4 (en) | 2017-09-29 | 2021-05-19 | Daiichi Sankyo Company, Limited | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
WO2019081455A1 (en) * | 2017-10-23 | 2019-05-02 | Mablink Bioscience | LIGAND-MEDICINAL CONJUGATE COMPRISING A UNIQUE MOLECULAR WEIGHT POLYSARCOSIN |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
KR20210008367A (ko) * | 2018-05-08 | 2021-01-21 | 페인스 테라퓨틱스 인코포레이티드 | 항-dll3 항체 및 이의 용도 |
CN112955153A (zh) | 2018-08-02 | 2021-06-11 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
EP3865151A4 (en) * | 2018-10-10 | 2022-11-16 | Takeda Pharmaceutical Company Limited | METHOD OF PREPARING AN ANTIBODY-DRUG CONJUGATE |
JP7401456B2 (ja) | 2018-11-14 | 2023-12-19 | 第一三共株式会社 | 抗cdh6抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
EP3950061A4 (en) | 2019-03-25 | 2022-11-16 | Daiichi Sankyo Company, Limited | ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
WO2020196475A1 (ja) | 2019-03-25 | 2020-10-01 | 第一三共株式会社 | 抗her2抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
KR20210143839A (ko) | 2019-03-27 | 2021-11-29 | 다이이찌 산쿄 가부시키가이샤 | 항체-피롤로벤조디아제핀 유도체 콘주게이트와 parp 저해제의 조합 |
MX2022000174A (es) * | 2019-07-02 | 2022-05-20 | Us Health | Anticuerpos monoclonales que se enlazan a egfrviii y sus usos. |
KR20220134584A (ko) * | 2020-01-31 | 2022-10-05 | 다인 세라퓨틱스, 인크. | 항-트랜스페린 수용체 (tfr) 항체 및 그의 용도 |
TW202227479A (zh) | 2020-09-02 | 2022-07-16 | 日商第一三共股份有限公司 | 新穎內-β-N-乙醯葡萄糖胺苷酶 |
EP4277664A1 (en) | 2021-01-13 | 2023-11-22 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
CA3231586A1 (en) * | 2021-09-17 | 2023-03-23 | Yunying CHEN | D3-binding molecules and uses thereof |
TW202346346A (zh) * | 2021-12-23 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗dll3抗體、其抗體-藥物偶聯物及其醫藥用途 |
US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101065151B (zh) * | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
EP1817341A2 (en) * | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
CN101336300A (zh) * | 2005-12-16 | 2008-12-31 | 健泰科生物技术公司 | 神经胶质瘤的诊断、预后和治疗方法 |
JP2010173975A (ja) * | 2009-01-30 | 2010-08-12 | Apro Life Science Institute Inc | タンパク質のリフォールディング組成物 |
SI3342786T1 (sl) * | 2010-01-29 | 2022-01-31 | Chugai Seiyaku Kabushiki Kaisha | Anti-DLL3 protitelo |
KR101772354B1 (ko) * | 2010-04-15 | 2017-08-28 | 시애틀 지네틱스, 인크. | 표적화된 피롤로벤조디아제핀 접합체 |
US20130028917A1 (en) * | 2010-04-15 | 2013-01-31 | Spirogen Developments Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
TWI651096B (zh) * | 2010-09-29 | 2019-02-21 | 美商艾澤西公司 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
KR20190089048A (ko) * | 2011-02-15 | 2019-07-29 | 이뮤노젠 아이엔씨 | 컨쥬게이트의 제조방법 |
US20130058947A1 (en) * | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
BR112014008888A2 (pt) * | 2011-10-14 | 2017-04-18 | Seattle Genetics Inc | pirrolobenzodiazepinas |
CN104520324A (zh) * | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
EP3107576A4 (en) * | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3 antibodies and drug conjugates for use in melanoma |
-
2014
- 2014-08-28 MX MX2016002545A patent/MX2016002545A/es unknown
- 2014-08-28 CN CN201480055223.6A patent/CN105873612A/zh active Pending
- 2014-08-28 AU AU2014312210A patent/AU2014312210A1/en not_active Abandoned
- 2014-08-28 CA CA2922544A patent/CA2922544A1/en not_active Abandoned
- 2014-08-28 BR BR112016004073A patent/BR112016004073A8/pt not_active Application Discontinuation
- 2014-08-28 KR KR1020167008241A patent/KR20160047567A/ko not_active Application Discontinuation
- 2014-08-28 PE PE2016000317A patent/PE20160209A1/es unknown
- 2014-08-28 SG SG11201601375VA patent/SG11201601375VA/en unknown
- 2014-08-28 EP EP14839261.6A patent/EP3038659A4/en not_active Withdrawn
- 2014-08-28 WO PCT/US2014/053304 patent/WO2015031693A1/en active Application Filing
- 2014-08-28 RU RU2016111137A patent/RU2016111137A/ru not_active Application Discontinuation
- 2014-08-28 JP JP2016537868A patent/JP2016531914A/ja active Pending
-
2016
- 2016-02-23 IL IL244254A patent/IL244254A0/en unknown
- 2016-02-26 PH PH12016500375A patent/PH12016500375A1/en unknown
- 2016-02-29 CL CL2016000468A patent/CL2016000468A1/es unknown
- 2016-02-29 US US15/056,893 patent/US20160175460A1/en not_active Abandoned
-
2017
- 2017-07-26 CL CL2017001916A patent/CL2017001916A1/es unknown
-
2018
- 2018-09-13 CL CL2018002620A patent/CL2018002620A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2015031693A1 (en) | 2015-03-05 |
BR112016004073A2 (pt) | 2017-10-17 |
PE20160209A1 (es) | 2016-05-09 |
AU2014312210A1 (en) | 2016-04-07 |
SG11201601375VA (en) | 2016-03-30 |
CA2922544A1 (en) | 2015-03-05 |
CL2018002620A1 (es) | 2018-12-14 |
EP3038659A4 (en) | 2017-07-26 |
IL244254A0 (en) | 2016-04-21 |
MX2016002545A (es) | 2016-06-17 |
EP3038659A1 (en) | 2016-07-06 |
KR20160047567A (ko) | 2016-05-02 |
CN105873612A (zh) | 2016-08-17 |
PH12016500375A1 (en) | 2016-05-02 |
US20160175460A1 (en) | 2016-06-23 |
CL2017001916A1 (es) | 2018-04-20 |
RU2016111137A3 (ru) | 2018-07-12 |
CL2016000468A1 (es) | 2016-12-09 |
BR112016004073A8 (pt) | 2018-06-12 |
JP2016531914A (ja) | 2016-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016111137A (ru) | Сконструированные конъюгаты против dll3 и способы применения | |
RU2016111131A (ru) | Способы конъюгации сайт-специфических антител и композиции | |
RU2014146951A (ru) | Конъюгаты типа лиганд dr5-лекарственное средство | |
JP2019532056A5 (ru) | ||
RU2021125492A (ru) | Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения | |
HRP20180015T1 (hr) | Anti-mezotelinski imunokonjugati i njihova uporaba | |
JP2016531915A5 (ru) | ||
RU2016117810A (ru) | Конъюгаты белок-полимер-лекарственное средство | |
HRP20200032T1 (hr) | Antitijelo lijek konjugati | |
PE20121552A1 (es) | Anticuerpos monoclonales anti cea humanizados de afinidad madura | |
RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
CN108137706A (zh) | 药物缀合的双特异性抗原结合构建体 | |
JP2015523380A5 (ru) | ||
RU2014120629A (ru) | Антиген-связывающий белок и его применение в качестве продукта для адресной доставки при лечении рака | |
CR9393A (es) | Anticuerpos anti-ccr5 y usos de los mismos | |
WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
MX2010005022A (es) | Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas. | |
JP2014522850A5 (ru) | ||
RU2010145177A (ru) | Лекарственное средство для лечения рака печени | |
ZA200508389B (en) | Humanized antibodies to interferon alpha receptor-1(IFNAR-1) | |
FI3316909T3 (fi) | NTB-A-vasta-aineita ja liittyviä koostumuksia ja menetelmiä | |
MX2012006420A (es) | Metodos para mejorar terapia con anticuerpos antitumor. | |
RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
SI2906296T1 (en) | Pyrrolobenzodiazepine-antibody conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190429 |